Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,796.00
(
0.00%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
109.75
(
2.97%
)
Bitcoin
70,173.45
(
-1.50%
)
News Focus
News Focus

Replies to post #68566 on Biotech Values

Replies to #68566 on Biotech Values
icon url

DewDiligence

11/14/08 5:22 PM

#68569 RE: DewDiligence #68566

Quiz: Why hasn’t Teva filed a Paragraph-IV challenge on Atripla as well as Truvada?
icon url

MRX22

11/14/08 6:06 PM

#68577 RE: DewDiligence #68566

Teva still would have to bust the tenofovir patents to be able to sell generic Truvada. 2 key Tenofovir patents survived the recent reexam and are likely a lot stronger than they were pre-reexam.